Are novel therapies set to revolutionise malignant melanoma?
Despite advances in the treatment of malignant melanoma (MM), demand still persists for improved modalities and outcomes. Newer targeted and immunotherapy combinations are emerging from the late-stage pipeline, but in a competitive landscape which assets will stand out? Want to find out more? Learn how KOLs see the malignant melanoma market evolving in Melanoma: KOL Insight (2017).
Twelve US and European KOLs provide candid insights on 9 marketed and 7 pipeline therapies targeting various aspects of the MM treatment algorithm.
Take a tour of the report now
- The table of contents
- The key business questions answered
- The key KOL quotes
- See the therapies covered
- Find out who the 6 EU & 6 US KOLs are
- Review an extract from the report - 1 drug profile
- Immune-oncology agents dominate the melanoma scene. Can Merck & Co.’s Keytruda maintain its position as the anti-PD-1 agent of choice? What advice do experts have for BMS’ Opdivo?
- Toxicity for BMS’ Yervoy remains a concern. Is the therapy on its way out or can lower dose (3mg/kg) Yervoy be as effective as the high dose (10mg/kg); find out what KOLs think?
- KOLs anticipate Opdivo will win approval in the adjuvant setting based on CheckMate-238 data. How will Keytruda’s KEYNOTE-054 study impact BMS’ franchise and which checkpoint inhibitor is likely to win?
- Single agent BRAF/MEK inhibitors are rarely prescribed but which combination (Roche’s Zelboraf/Cotellic or GSK’s Mekinist/Tafinlar) do KOLs favour? Array’s new encorafenib/binimetinib combination is on the way; can it compete?
- Is there any future for Amgen’s Imlygic? Viewed as a niche product by experts, can combination therapy with immune-oncology agents salvage Imlygic?
- Does Incyte’s IDO inhibitor, epacadostat have any potential? How do experts rate this novel mechanism of action for melanoma?
- What do experts say about Novartis’ PDR 001 and Roche’s atezolizumab? How do they rate the chances of these novel checkpoint inhibitors in light of ever increasing competition?
- Anti-PD-1/BRAF/MEK combinations are on the horizon. Which triplet regimens hold the most promise and what concerns do experts have with these multi-drug combinations?
“The more we learn about mechanisms of both de novo and acquired resistance and what the underpinnings for melanoma subsets that are particularly hard to treat, I think we're going to have a much bigger toolbox to put things together and really move the [treatment] plateaus up a bit more.” EU Key Opinion Leader
“I'm excited about the IDO inhibitor paradigm and other combinations that can be designed, in an intelligent way, to get at particular cases that are non-responsive to single agent drugs.”EU Key Opinion LeaderMarketed Therapies
- Cotellic (Exelixis/Roche)
- IMLYGIC (Amgen)
- Keytruda (Merck & Co.)
- Mekinist (Novartis)
- M-Vax (AVAX Technologies)
- Opdivo (Bristol-Myers Squibb/Ono Pharmaceuticals)
- Tafinlar (Novartis)
- Yervoy (Bristol-Myers Squibb)
- Zelboraf (Roche/Genentech/Chugai)
KOLs interviewedKOLs from North America
- Atezolizumab (Genentech/Roche)
- Binimetinib (Array BioPharma; Novartis)
- Darleukin (Philogen)
- Encorafenib (Array BioPharma/Novartis)
- Epacadostat (Incyte/Merck & Co.)
- PDR 001 (Novartis)
- Seviprotimut-L (Polynoma)
KOLs from Europe
- Anna C Pavlick, DO, Professor, Hematology and Medical Oncology and Medical Director Perlmutter Cancer Center Clinical Trials Office NYU Langone Medical Center, New York City, NY
- Kim A Margolin, MD, Medical Oncologist, Clinical Professor, City of Hope, Department of Medical Oncology & Therapeutics Research, University of Washington, Seattle, WA
- Philip A. Friedlander MD, PhD, Assistant Professor, Department of Dermatology, Mount Sinai School of Medicine, New York City, NY
- Rene-Gonzalez_Catarelo MD, Oncology Specialist, Memorial Hospital and University of Colorado Hospital, Aurora, Denver, CO
- Roger S. Lo, MD, PhD, Assistant Professor, Medicine and Molecular & Medical Pharmacology, Department of Medicine at UCLA, Los Angeles, CA
- Sanjiv S Agarwala, MD, Professor, Temple University School of Medicine, Chief of Medical Oncology and Hematology, St. Luke’s University Hospital & Health Network, Bethlehem, Philadelphia, PA
- Ana Arance MD, PhD, Professor, Department of Medical Oncology, Hospital Clínic Barcelona, Villarroel 170, 08036 Barcelona, Spain
- Anonymous German KOL, Prof. Dr., Professor of Dermatology and Director at a teaching hospital in Germany
- Christian Blank, MD, PhD, Professor Dr, Group Leader Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands
- Jean-Jacques Grob, MD, Head of the Dermatology and Skin cancer Department, Timone APHM Hospital and Aix-Marseille University, Marseille, France
- Paul D Nathan, MBBS, PhD, FRCP, Consultant Medical Oncologist, Mount Vernon Cancer Centre, East and North Herts NHS Trust, Northwood, Middlesex, UK
- Caroline Robert, MD, PhD, Professor & Head of the Dermatology Unit at the Gustave Roussy Cancer Centre, Villejuif-Paris, France
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.Ongoing Benefits
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
- Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
- You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
- 1. Executive summary
- 2. Research objectives
- 3. Research focus
- 3.1 Malignant melanoma treatment
- 3.2 Checkpoint inhibitors and the arrival of Imlygic, the first oncolytic immunotherapy
- 4. Marketed therapies
- 4.1 Overview
- 5. Immunotherapies
- 5.1 Marketed drugs
- 5.1.1 Yervoy (ipilimumab; Bristol-Myers Squibb)
- 5.1.2 Keytruda (pembrolizumab; Merck & Co.)
- 5.1.3 Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical)
- 6. BRAF/MEK inhibitors 54
- 6.1 Overview
- 6.2 Marketed BRAF/MEK drugs
- 6.2.1 Zelboraf (vemurafenib; Roche/Genentech/Chugai)
- 6.2.2 Tafinlar (dabrafenib; Novartis)
- 6.2.3 Mekinist (trametinib; Novartis)
- 6.2.4 Cotellic (cobimetinib; Exelixis/Roche)
- 7. Melanoma vaccines/immunostimulants
- 7.1 Overview
- 7.2 Marketed drugs
- 7.3 M-Vax (melanoma vaccine; AVAX Technologies)
- 7.4 Imlygic (talimogene laherparepvec; Amgen)
- 8. Pipeline therapies
- 8.1 Overview
- 9. BRAF/MEK inhibitors
- 10. Overview
- 10.1 Binimetinib (Array BioPharma/Novartis)
- 10.2 Encorafenib (Array BioPharma/Novartis)
- 11. IDO1 inhibitor
- 11.1 Overview
- 11.1.1 Epacadostat (Incyte/Merck & Co.)
- 12. PD-1/L1 & angiogenic inhibitors
- 12.1 Overview
- 12.1.1 Atezolizumab (Genentech (Roche))
- 12.1.2 PDR 001 (Novartis)
- 12.1.3 Darleukin (L19-IL2; Philogen)
- 13. Immunostimulants/vaccines
- 13.1 Overview
- 13.1.1 Seviprotimut-L (POL 103A; Polynoma)
- 14. Conclusion
- 14.1 Current and future treatment algorithm
- 15. Appendix
- 15.1 KOL details
- 15.1.1 KOLs from North America
- 15.1.2 KOLs from Europe